A detailed history of Credit Suisse Ag transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 316,693 shares of ADMA stock, worth $3.55 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
316,693
Previous 339,650 6.76%
Holding current value
$3.55 Million
Previous $1.54 Million 36.16%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$4.4 - $6.74 $101,010 - $154,730
-22,957 Reduced 6.76%
316,693 $2.09 Million
Q4 2023

Feb 08, 2024

SELL
$3.08 - $4.52 $1,567 - $2,300
-509 Reduced 0.15%
339,650 $1.54 Million
Q3 2023

Nov 13, 2023

SELL
$3.47 - $4.61 $204,830 - $272,123
-59,029 Reduced 14.79%
340,159 $1.22 Million
Q2 2023

Aug 11, 2023

BUY
$3.12 - $4.22 $517,218 - $699,570
165,775 Added 71.02%
399,188 $1.47 Million
Q1 2023

May 10, 2023

BUY
$3.01 - $3.87 $31,144 - $40,042
10,347 Added 4.64%
233,413 $772,000
Q4 2022

Feb 13, 2023

BUY
$2.47 - $3.88 $548,342 - $861,363
222,001 Added 20845.16%
223,066 $865,000
Q3 2022

Nov 10, 2022

BUY
$2.03 - $2.86 $1,977 - $2,785
974 Added 1070.33%
1,065 $3,000
Q2 2022

Aug 12, 2022

BUY
$1.43 - $2.2 $130 - $200
91 New
91 $0
Q4 2021

Feb 14, 2022

SELL
$1.09 - $1.66 $38,150 - $58,100
-35,000 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$1.13 - $1.65 $39,549 - $57,750
35,000 New
35,000 $40,000
Q2 2021

Aug 16, 2021

SELL
$1.51 - $2.07 $27,675 - $37,938
-18,328 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$1.67 - $2.95 $6,168 - $10,897
3,694 Added 25.24%
18,328 $32,000
Q4 2020

Feb 12, 2021

BUY
$1.8 - $2.56 $26,341 - $37,463
14,634 New
14,634 $28,000
Q4 2019

Feb 12, 2020

SELL
$3.89 - $5.15 $47,310 - $62,634
-12,162 Closed
0 $0
Q3 2019

Nov 12, 2019

BUY
$3.19 - $5.39 $38,796 - $65,553
12,162 New
12,162 $54,000

Others Institutions Holding ADMA

About ADMA BIOLOGICS, INC.


  • Ticker ADMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 196,356,992
  • Market Cap $2.2B
  • Description
  • ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...
More about ADMA
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.